FEMASYS INC (FEMY): Nasdaq/NYSE listing notice — Femasys granted 180-day extension to cure Nasdaq minimum bid price deficiency

FEMASYS INC

Received Nasdaq deficiency notice July 16, 2025; bid price below $1.00 for 30 consecutive days.
Granted extension to July 13, 2026 after requesting 180-day extension on Jan 12, 2026.
Company reported stockholders' equity over $5M as of Dec 31, 2025; plans reverse stock split if needed.
Common stock ticker FEMY remains listed on Nasdaq Capital Market during extension period.
Non-compliance continues; risk of delisting if not cured by July 13, 2026.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

FEMASYS INC received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 13, 2026, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to July 13, 2026 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and July 13, 2026, and will consider available options to resolve the deficiency, including effecting a reverse stock split as stated above, and regain compliance with the Minimum Bid Price Requirement. SIGNATURE Pursuant to t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-001268

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.